METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific gene change (SPOP mutation) and is no longer responding to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 can…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug combo shows promise against Hard-to-Treat prostate cancer
Disease control OngoingThis study tests whether combining two drugs—golimumab (which reduces inflammation) and apalutamide (which blocks male hormones)—can shrink or slow advanced prostate cancer that no longer responds to standard hormone therapy. Eight men with metastatic castration-resistant prostat…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New scan could sharpen prostate cancer detection
Diagnosis OngoingThis study tests a special PET scan called 68Ga-PSMA-11 to see if it can find prostate cancer more clearly than standard scans. About 141 men with prostate cancer that has come back or spread will get this scan. The goal is to see if the scan changes how doctors plan treatment, s…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Diagnosis
Last updated May 17, 2026 09:20 UTC